A new test for the early detection of Alzheimer’s Disease — potentially even before symptoms are present — show that the diagnostic caught the neurodegenerative disease in 100% of the samples from patients symptomatic for Alzheimer’s.
Researchers at the University of Washington and Seattle biotech startup AltPep are building on a track record of success with their latest publication.
Their study used 265 blood plasma samples from two different organizations and tested them in two different laboratories by different personnel.